



## ECCO CALL for ECCO Participants in the ECCO-ESPGHAN Guidelines Update on Paediatric CD Treatment 2018-2020

### Context and aim of the project:

- Children and adolescents with Crohn's disease (CD) often present a more complicated disease course compared to adult patients. In addition, the potential impact of CD on growth, pubertal and emotional development in patients underlines the need for a specific management strategy of paediatric CD. In 2014 the first consensus guidelines of ECCO/ESPGHAN were published in the Journal of Crohn's and Colitis. Since then, new relevant therapeutic trials have been published that justify to update the guidelines. The aim is to form an expert panel of IBD specialists after an open call within ECCO and ESPGHAN, and to provide detailed evidence-based recommendations and practice points for the treatment of children with CD.

You may be familiar with the concept of the ECCO Consensus Guidelines. In brief, working parties prepare statements and the supporting text prior to a plenary Consensus session. At this meeting Consensus statements will be discussed, modified and accepted or rejected by the expert panel.

Afterwards the statements are no longer amenable to change and the text detailing the supportive evidence is finalised for publication in the Journal of Crohn's and Colitis (JCC).

To facilitate the Consensus process, the ECCO participants will be selected for the Workgroups of this Consensus Panel on the basis of applications to this call. ESPGHAN will also nominate participants via a simultaneous call. Once selected, group members will be assigned to the relevant topic areas and expected to draft jointly their respective manuscript part.

ECCO traditionally reserves **1 seat in each working group for a Y-ECCO participant** who will specifically be in charge of the systematic bibliographic review, the draft of the supporting text and further development of e-Learning material. You are very welcome to apply for this project.

### If you:

- are an ECCO Member (in good standing – Membership 2018);
- are interested in joining one of the working parties
- are able to personally commit to delivering the work involved in the guideline generation;
- have extensive experience in treating children with CD and relevant IBD publications;
- have proven scientific writing skills, demonstrated skills in evidence-based medicine, and preferably have previous experience of conducting systematic reviews
- are able to attend the Final F2F Consensus meeting (tentative date -TBC: Sunday, October 20, 2019 at UEGW'19)

### Governing Board

#### President

Silvio Danese  
Italy

#### President-Elect

Laurent Peyrin-Biroulet  
France

#### Past-President

Julián Panés  
Spain

#### Secretary

Willem Bemelman  
The Netherlands

#### Treasurer

Ailsa Hart  
United Kingdom

#### Education Officer

James Lindsay  
United Kingdom

#### Scientific Officer

Gerhard Rogler  
Switzerland

#### ECCO Office

Ungargasse 6/13  
1030 Vienna, Austria

Tel. +43-(0)1-710 22 42  
Fax +43-(0)1-710 22 42-001  
E-Mail [ecco@ecco-ibd.eu](mailto:ecco@ecco-ibd.eu)  
Url [www.ecco-ibd.eu](http://www.ecco-ibd.eu)

SWIFT GIBAATWWXXX  
IBAN AT5720111 28748039100

ATU 63674955  
Austrian Register of Associations  
N° 468755685  
DPR Number: N°4003204



European  
Crohn's and Colitis  
Organisation

please send an e-mail to [ecco@ecco-ibd.eu](mailto:ecco@ecco-ibd.eu) detailing (\*):

- your name and affiliations;
- and a short (max. 10 lines) profile of yourself as an expert in the field.

**Deadline for submission is October 8, 2018**

*\*Data processing consent and retention: By sending an application by email to [ecco@ecco-ibd.eu](mailto:ecco@ecco-ibd.eu), you agree to the data processing for the above described project: ECCO Office stores applicants' personal data of this application for the project timeframe. You have the right to object at any time at [ecco@ecco-ibd.eu](mailto:ecco@ecco-ibd.eu). ECCO Office will delete data securely after the end of this project.*

**Topics and questions will be addressed in these proposed Working Groups:**

WG1: Remission induction: exclusive enteral nutrition

WG2: Remission induction: steroids

WG3: Maintenance therapy: Thiopurines, methotrexate, use of thiopurine metabolites

WG4: Biological therapy: Anti-TNFs, anti-integrin, use of trough levels

WG5: Refractory CD: Off-label drugs

ECCO is looking forward to your application!

On behalf of the P-ECCO Committee

**Governing Board**

*President*

Silvio Danese  
Italy

*President-Elect*

Laurent Peyrin-Biroulet  
France

*Past-President*

Julián Panés  
Spain

*Secretary*

Willem Bemelman  
The Netherlands

*Treasurer*

Ailsa Hart  
United Kingdom

*Education Officer*

James Lindsay  
United Kingdom

*Scientific Officer*

Gerhard Rogler  
Switzerland

*ECCO Office*

Ungargasse 6/13  
1030 Vienna, Austria

Tel. +43-(0)1-710 22 42  
Fax +43-(0)1-710 22 42-001  
E-Mail [ecco@ecco-ibd.eu](mailto:ecco@ecco-ibd.eu)  
Url [www.ecco-ibd.eu](http://www.ecco-ibd.eu)

SWIFT GIBAAWXXXX  
IBAN AT5720111 28748039100

ATU 63674955  
Austrian Register of Associations  
N° 468755685  
DPR Number: N°4003204